These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16311019)

  • 1. Pharmacogenetics of autoimmune diseases: research issues in the case of Multiple Sclerosis and the role of IFN-beta.
    Macciardi F; Martinelli Boneschi F; Cohen D
    J Autoimmun; 2005; 25 Suppl():1-5. PubMed ID: 16311019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.
    Foti Cuzzola V; Palella E; Celi D; Barresi M; Giacoppo S; Bramanti P; Marino S
    Pharmacogenomics J; 2012 Dec; 12(6):453-61. PubMed ID: 23044601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
    Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
    Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interferon -beta therapy in multiple sclerosis].
    Satoh J
    Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: pharmacogenomics and personalised drug treatment.
    Annibali V; Ristori G; Cannoni S; Romano S; Visconti A; Ghazaryan A; Figà Talamanca L; Salvetti M; Mechelli R
    Neurol Sci; 2006 Sep; 27 Suppl 5():S347-9. PubMed ID: 16998717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple sclerosis].
    Offenhäusser M; Martin R
    Med Monatsschr Pharm; 1997 Jun; 20(6):149-57. PubMed ID: 9289627
    [No Abstract]   [Full Text] [Related]  

  • 7. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
    Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
    Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
    Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K
    Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
    Carlson RJ; Doucette JR; Knox K; Nazarali AJ
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.
    O'Doherty C; Villoslada P; Vandenbroeck K
    Cytokine Growth Factor Rev; 2007; 18(3-4):211-22. PubMed ID: 17540610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.
    Sriram U; Barcellos LF; Villoslada P; Rio J; Baranzini SE; Caillier S; Stillman A; Hauser SL; Montalban X; Oksenberg JR
    Genes Immun; 2003 Mar; 4(2):147-52. PubMed ID: 12618863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.
    Vosslamber S; van Baarsen LG; Verweij CL
    Pharmacogenomics; 2009 Jan; 10(1):97-108. PubMed ID: 19102719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
    Vandenbroeck K; Matute C
    Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.
    Alvarez-Lafuente R; Blanco-Kelly F; Garcia-Montojo M; Martínez A; De Las Heras V; Dominguez-Mozo MI; Bartolome M; Garcia-Martinez A; De la Concha EG; Urcelay E; Arroyo R
    Mult Scler; 2011 May; 17(5):513-20. PubMed ID: 21177319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.
    Vandenbroeck K; Comabella M
    J Interferon Cytokine Res; 2010 Oct; 30(10):727-32. PubMed ID: 20836710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis: where will we be in 2020?
    Miller AE
    Mt Sinai J Med; 2011; 78(2):268-79. PubMed ID: 21425270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
    Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
    Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.